Abstract
Emerging evidence suggests BRCA1/2 or ATM gene mutation status in metastatic pancreatic cancer (mPC) could predict clinical benefit from platinum-based chemotherapy and targeted therapies. We examined treatment patterns by BRCA 1/2/ATM mutation status in patients with mPC receiving routine care in the United States.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have